BRANDON PALMER: Open Payments
NPI 1205134939 · COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$938 in 57 payments from 18 companies in 2025. Trend: 2023 $1,793 · 2024 $809 · 2025 $938
Food & beverage: $938
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $169 |
| Amgen Inc. | 8 | $133 |
| Abbott Laboratories | 4 | $80 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $80 |
| Novo Nordisk Inc | 3 | $67 |
| AstraZeneca Pharmaceuticals LP | 4 | $62 |
| Edwards Lifesciences Corporation | 2 | $52 |
| Lilly USA, LLC | 2 | $48 |
| Exact Sciences Corporation | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
Products named: OTEZLA, VRAYLAR, XIFAXAN, JARDIANCE, SAPIEN 3 Ultra RESILIA, FARXIGA, REXULTI, Wegovy.
Industry payments across SC — which companies pay providers there.
